Oryzon Genomics S.A. – LSE:0RDB.L
Oryzon Genomics S.A. stock price today
Oryzon Genomics S.A. stock price monthly change
Oryzon Genomics S.A. stock price quarterly change
Oryzon Genomics S.A. stock price yearly change
Oryzon Genomics S.A. key metrics
Market Cap | 97.71M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.05 |
Revenue | N/A |
EBITDA | -4.28M |
Income | -3.11M |
Revenue Q/Q | N/A |
Revenue Y/Y | -66.45% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOryzon Genomics S.A. stock price history
Oryzon Genomics S.A. stock forecast
Oryzon Genomics S.A. financial statements
| Jun 2023 | 8.16M | 1.15M | 14.1% |
|---|---|---|---|
| Sep 2023 | 0 | -1.12M | |
| Dec 2023 | 0 | -1.90M | |
| Mar 2024 | 0 | -1.23M |
| 2025 | 1.90M | 4.11M | 215.71% |
|---|---|---|---|
| 2026 | 4.02M | 3.60M | 89.53% |
| 2027 | 259.11M | 115.26M | 44.49% |
| 2028 | 478.08M | 210.05M | 43.94% |
Analysts Price target
Financials & Ratios estimates
| Dec 2021 | 0 | 24.12M | Infinity% |
|---|---|---|---|
| Jun 2022 | 0 | 26.21M | Infinity% |
| Dec 2022 | 0 | 31.12M | Infinity% |
| Jun 2023 | 114180994 | 28.48M | 24.94% |
| Jun 2023 | 0 | 0 | 0 |
|---|---|---|---|
| Sep 2023 | 0 | 0 | 0 |
| Dec 2023 | 0 | 0 | 0 |
| Mar 2024 | 0 | 0 | 0 |
Oryzon Genomics S.A. alternative data
| Aug 2023 | 43 |
|---|---|
| Sep 2023 | 43 |
| Oct 2023 | 43 |
| Nov 2023 | 43 |
| Dec 2023 | 43 |
| Jan 2024 | 43 |
| Feb 2024 | 43 |
| Mar 2024 | 43 |
| Apr 2024 | 43 |
| May 2024 | 43 |
| Jun 2024 | 43 |
| Jul 2024 | 43 |
Oryzon Genomics S.A. other data
| Insider | Compensation |
|---|---|
Dr. Carlos Manuel Buesa Arjol Co-Founder, Chairman, Chief Executive Officer & Pres | $58,000 |
Mr. Enric Rello Chief Operating Officer & Chief Financial Officer | |
Dr. Torsten Hoffmann Chief Scientific Officer | |
Mr. Emili Torrell Chief Bus. Devel. Officer | |
Ms. Neus Virgili Chief Intellectual Property Officer | |
Dr. Cesar Molinero Chief Clinical Officer | |
Dr. Roger Bullock Chief Medical Officer | |
Ms. Sonia Gutierrez Chief of Clinical Operations | |
Mr. Augusto Pinel Rubio Sec. |
-
What's the price of Oryzon Genomics S.A. stock today?
One share of Oryzon Genomics S.A. stock can currently be purchased for approximately $2.79.
-
When is Oryzon Genomics S.A.'s next earnings date?
Unfortunately, Oryzon Genomics S.A.'s (0RDB.L) next earnings date is currently unknown.
-
Does Oryzon Genomics S.A. pay dividends?
No, Oryzon Genomics S.A. does not pay dividends.
-
How much money does Oryzon Genomics S.A. make?
Oryzon Genomics S.A. has a market capitalization of 97.71M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 6.79% to 15.67M US dollars.
-
What is Oryzon Genomics S.A.'s stock symbol?
Oryzon Genomics S.A. is traded on the LSE under the ticker symbol "0RDB.L".
-
What is Oryzon Genomics S.A.'s primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Oryzon Genomics S.A.?
Shares of Oryzon Genomics S.A. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Oryzon Genomics S.A.'s key executives?
Oryzon Genomics S.A.'s management team includes the following people:
- Dr. Carlos Manuel Buesa Arjol Co-Founder, Chairman, Chief Executive Officer & Pres()
- Mr. Enric Rello Chief Operating Officer & Chief Financial Officer
- Dr. Torsten Hoffmann Chief Scientific Officer
- Mr. Emili Torrell Chief Bus. Devel. Officer
- Ms. Neus Virgili Chief Intellectual Property Officer
- Dr. Cesar Molinero Chief Clinical Officer
- Dr. Roger Bullock Chief Medical Officer
- Ms. Sonia Gutierrez Chief of Clinical Operations
- Mr. Augusto Pinel Rubio Sec.
-
Is Oryzon Genomics S.A. founder-led company?
Yes, Oryzon Genomics S.A. is a company led by its founder Dr. Carlos Manuel Buesa Arjol.
-
How many employees does Oryzon Genomics S.A. have?
As Jul 2024, Oryzon Genomics S.A. employs 43 workers.
-
When Oryzon Genomics S.A. went public?
Oryzon Genomics S.A. is publicly traded company for more then 8 years since IPO on 15 Dec 2016.
-
What is Oryzon Genomics S.A.'s official website?
The official website for Oryzon Genomics S.A. is oryzon.com.
-
How can i contact Oryzon Genomics S.A.?
Oryzon Genomics S.A. can be reached via phone at +34 935 15 13 13.
Oryzon Genomics S.A. company profile:
Oryzon Genomics S.A.
oryzon.comLSE
46
Medical - Pharmaceuticals
Healthcare
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Cornellà de Llobregat, 08940
:
ISIN: ES0167733015
CUSIP: E7S54Q107
